Quisqualis fruit extract powder,
does it really help with Prostate health and improved urinary symptoms?
research showsA two-center 12-week double-blind RCT randomized 135 men to the proprietary HU033 extract powder and analyzed 113 per protocol, finding improved IPSS. Qmax and PVR were not consistent across doses and time points, and clinical outcomes such as urinary retention or surgery were not assessed. Public support for the study must be distinguished from the HUONS-developed ingredient lineage; one developer-specific trial results in C.
ads claimProduct descriptions may expand improved urinary symptom scores into prostate shrinkage, treatment of benign prostatic hyperplasia, or prevention of progression. The directly supported scope is the 12-week IPSS change in men with moderate symptoms.
Useful facts when choosing a product
- The HU033 trial material was a 70% ethanol extract of Quisqualis seeds mixed 1:1 with maltodextrin.
- Trial doses were 1,000 mg/day and 2,000 mg/day for 12 weeks.
- The key outcome was the patient-reported IPSS questionnaire; prostate volume was not measured.
- Two product-related adverse events were reported, while long-term and rare-event data remain limited.
What the research actually shows
The 2023 study by Shin and colleagues randomized 135 men with IPSS scores of 8-19 at two centers to HU033 at 1,000 mg/day, 2,000 mg/day, or placebo and analyzed 113 per protocol. Total IPSS at weeks six and 12 improved with both doses. Qmax and PVR improved only at selected doses and time points and were not consistent overall; acute urinary retention and surgery were not evaluated. Public support for the study should be distinguished from the fact that HU033 was developed by HUONS, rather than described as direct company sponsorship.
Why this is classified as C (54)
The positive IPSS signal from a two-center RCT is credible, but direct evidence is limited to one 12-week trial of the HUONS-developed HU033 material. Inconsistent Qmax and PVR, no independent replication, and no urinary-retention or surgery outcome result in C with 54 points. Public support is distinguished from direct company sponsorship.
Counterpoint. A signal for improved patient-reported symptoms over 12 weeks remains in men with moderate lower urinary tract symptoms. This assessment does not extend it to prostate shrinkage or long-term disease prevention.
Rejudgment record. Reassessment (cross-check reflected) — A two-center trial of the proprietary HU033 powder randomized 135 and analyzed 113 per protocol, with positive IPSS but inconsistent Qmax and PVR, no urinary-retention or surgery outcomes, and no independent replication; public support is distinguished from the HUONS-developed ingredient lineage
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved lower urinary tract and urinary symptoms | C | IPSS was positive in one 12-week RCT, without independent replication. |
| Improved objective urinary flow and residual volume | C | Findings appeared only in selected analyses such as the low-dose group at week six and were not consistent across doses and time points. |
| Reduced prostate size or slowed disease progression | ? | No direct human literature was identified evaluating prostate volume or long-term progression outcomes. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Shin D et al. 2023 | Two-center randomized double-blind placebo-controlled trial | 12 | Public National Research Foundation support; standardized HUONS material | IPSS, Qmax, PVR, PSA, hormones, and IIEF-5 | Total IPSS improved with both doses versus placebo, while objective measures were not consistent across doses and time points. | Key |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-07-11).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Quisqualis fruit extract powder (Combretum indicum) × Prostate health and improved urinary symptoms — Evidence Grade C·54. 1 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/mens/quisqualis-fruit-extract-prostate-urination/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.